Citi lowered the firm’s price target on Integra LifeSciences (IART) to $9 from $11 and keeps a Sell rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra’s MicroMatrix Flex Study Reaches Completion, Setting Up Next Steps for IART Investors
- Integra Lifesciences Charts Cautious Path After Earnings
- Integra LifeSciences price target lowered to $11 from $13 at JPMorgan
- Integra LifeSciences price target lowered to $12 from $13 at Wells Fargo
- Integra LifeSciences files automatic mixed securities shelf